Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00843882 · OUTCOME

Time to Major Erythroid Response (MER)

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia · Source last updated 2026-09-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Assessed every cycle during treatment and then 3 and 6 months after last protocol treatment

What was measured

Time to major erythroid response (MER) is defined in responders as the time from randomization to the documented date of MER. For transfusion independent patients, the date of MER is the first date of the elevation in hemoglobin level of more than 2 g/dL that has been sustained for at least 8 weeks. For transfusion dependent patients, the date of MER is the beginning date of the time interval of transfusion independence that has been sustained for at least eight weeks.

Analysis population: Only evaluable patients who achieved MER among randomized patients were included in this analysis.

Groups in this outcome

Arm A (Lenalidomide; Randomization)

Patients receive lenalidomide PO QD on days 1-21.

Arm B (Lenalidomide + Epoetin Alfa; Randomization)

Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A (Lenalidomide; Randomization)11
Arm B (Lenalidomide + Epoetin Alfa; Randomization)28

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Arm A (Lenalidomide; Randomization)3.6Not reported2.15.5Not reported
Arm B (Lenalidomide + Epoetin Alfa; Randomization)3.7Not reported1.010.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.1
        upper Limit
        5.5
        value
        3.6
      2. group Id
        OG001
        lower Limit
        1.0
        upper Limit
        10.6
        value
        3.7
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    2. group Id
      OG001
      value
      28
    units
    Participants
description
Time to major erythroid response (MER) is defined in responders as the time from randomization to the documented date of MER. For transfusion independent patients, the date of MER is the first date of the elevation in hemoglobin level of more than 2 g/dL that has been sustained for at least 8 weeks. For transfusion dependent patients, the date of MER is the beginning date of the time interval of transfusion independence that has been sustained for at least eight weeks.
dispersion Type
Full Range
groups
  1. description
    Patients receive lenalidomide PO QD on days 1-21.
    id
    OG000
    title
    Arm A (Lenalidomide; Randomization)
  2. description
    Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.
    id
    OG001
    title
    Arm B (Lenalidomide + Epoetin Alfa; Randomization)
param Type
MEDIAN
population Description
Only evaluable patients who achieved MER among randomized patients were included in this analysis.
reporting Status
POSTED
time Frame
Assessed every cycle during treatment and then 3 and 6 months after last protocol treatment
title
Time to Major Erythroid Response (MER)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice